Helsinn Holding

For the last 45 years, Helsinn has functioned as a Lugano, Switzerland-based pharmaceutical and biotechnology company that has secured numerous pharmaceutical drug patents. Established by Dr. Gabriele Braglia in 1976 as a pharmaceutical licensing operation, the organization employs nearly 700 workers and manages a portfolio of comprehensive cancer care, cancer therapeutics and rare disease therapies with the help of numerous commercial and marketing partners. A family business, Helsinn is led by vice chairman and chief executive officer Riccardo Braglia.

As a global operator with a 360 degree approach to quality control, the Swiss company has established multiple offices and manufacturing facilities around the world, including Ireland, China, and the United States. In addition, its subsidiary Helsinn Advanced Synthesis SA operates as a full service contract manufacturing organization and has held a good manufacturing practice certificate since 1984.

Helsinn achieved Global CEO Cancer Gold Standard Accreditation in 2018 and is a supporter of cancer-related charitable organizations such as the Conquer Cancer Foundation. The company also supports Africa’s New Flower Foundation, which promotes education throughout the African continent. To learn more about Helsinn and its various lines of cancer care products, visit helsinn.com.